Following its Annual General Meeting on September 4, 2026, Evogene Ltd. reported that dissident shareholders L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd. challenged the voting results and issued notice of intent to launch a special tender offer under Israeli law. Concurrently, directors Yoshinori Oikawa and Dr. Yael Margolin resigned from the board on September 9, 2026, with no stated disagreements regarding company operations or policies. The Company is currently engaging in discussions with these shareholders to resolve the disputes. Evogene Ltd. operates in the biotechnology industry, focusing on drug discovery and development using its proprietary platforms.

Evogene Ltd. reported second quarter and first half 2026 financial results on August 18, 2026. The company reduced its net loss to approximately $1.8 million for the quarter, down from $4.7 million in the prior year period. Cash burn is expected to decline to $8.5–$9.5 million in 2026, compared with $14.4 million in 2025. Evogene raised approximately $11.1 million in new capital since early 2025 and holds $9.3 million in cash as of June 30, 2026. The company expanded its virtual chemical space to 110 billion molecules and integrated autonomous AI Agents via a partnership with Google Cloud. It also established six active drug development collaborations and advanced internal programs toward lead optimization. Evogene operates in the computational chemistry industry, specializing in the generative design of small molecules for pharmaceutical and agricultural applications.

Evogene Ltd. filed a Form 6-K announcing its 2026 Annual General Meeting scheduled for September 4, 2026, with a record date of August 11, 2026. The filing discloses that Ms. Olga Nissan stepped down as VP Business Development effective July 31, 2026. Shareholders will vote on a contested director election between the Board's seven-member Evogene Slate and a four-member slate nominated by L.I.A Pure Capital Ltd. and Invest-Pro Shukai Hon Ltd., who hold approximately 14.67% of voting rights. Proposals also include increasing authorized share capital by 120,000,000 shares to NIS 30,000,000 and approving a framework for the Board to execute a reverse stock split at a ratio between 1-for-2 and 1-for-15 within 18 months. Evogene Ltd. operates in the biotechnology industry, focusing on AI-driven computational chemistry and drug discovery.

Evogene Ltd. increased its at-the-market offering amount from $2,926,500 to $3,288,113 under its Sales Agreement with A.G.P./Alliance Global Partners. The company also updated its risk factors to include risks associated with shareholder activism and potential proxy contests, following a demand by certain shareholders to call an extraordinary general meeting to replace most of the Board of Directors. Evogene Ltd. is a biotechnology company focused on on-demand plant-based solutions.